



Perinatal Depression SSRIs and Pregnancy Risk-Risk Conversation *Facilitator's Guide*

Contributors

Sarah M. Nagle-Yang, MD, University of Colorado School of Medicine

Priya Gopalan, MD, University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic

Eydie Moses-Kolko, MD, University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic

Allison Foroobar, MD, University of Pittsburgh Medical Center/Western Psychiatric Institute and Clinic

Pre-Assessment Learning

- Payne JL. Psychiatric Medication Use in Pregnancy and Breastfeeding. *Obstet Gynecol Clin North Am.* 2021 Mar;48(1):131-149. doi: 10.1016/j.ogc.2020.11.006. PMID: 33573783.
- Wisner KL, Oberlander TF, Huybrechts KF. The Association Between Antidepressant Exposure and Birth Defects-Are We There Yet? *JAMA Psychiatry.* 2020 Aug 5. doi: 10.1001/jamapsychiatry.2020.1512. Epub ahead of print. PMID: 32777006.
- Yonkers, Kimberly A., et al. "The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists." *General hospital psychiatry* 31.5 (2009): 403-413.

Additional Reading (optional)

- Moses-Kolko, Eydie L., et al. "Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications." *Jama* 293.19 (2005): 2372-2383.

Session Overview

- Introduction to Session and Case Discussion [20 minutes]
- [Video \[15 minutes\]](#)
- Small Group Activity [20 minutes]
- Large Group Discussion: Take-Home Points [5 minutes]

Learning Objectives

1. The learner will describe risks associated with untreated depression in pregnancy and postpartum
2. The learner will formulate a perinatal case with a focus on depression management
3. The learner will practice risk-risk discussions in pregnancy
4. The learner will appreciate unique factors in the management of perinatal depression in the context of risks of both medications and untreated psychiatric illness



Case Scenario

Ms. D is a 25yo G1 female at 24 weeks gestation who presents for an initial evaluation with chief complaints of depression and anxiety. Ms. D has had difficulty finding a provider who is comfortable managing her psychiatric medications during her pregnancy and found your name on your institution's website.

Psychiatric History: Ms. D has been treated for depression since age 18. She reports that when depressed her symptoms include low mood, hypersomnia, anhedonia, avolition, and feeling “overwhelming frustration and hopelessness.” She states that when she has been at her worst, she was “completely not functional, in bed 23.5 hours a day.” Anxiety symptoms seem to occur in conjunction with depressive episodes and are characterized by constant worry, feeling easily overwhelmed, restless, “edgy,” and tense.

Ms. D has periodically struggled with suicidal thoughts but has never had an attempt. She was hospitalized in 2015 for acute suicidality with plan to overdose on “pills and liquor.” At other points, she has struggled with thoughts that it would be easier to die than to live with her depression.

Ms. D has had several medication trials in the past, including sertraline (ineffective at 200mg daily for 10 weeks), venlafaxine (ineffective at 225mg daily for 8 weeks), paroxetine (worked well but caused weight gain), and bupropion (exacerbated anxiety and was discontinued). Her current medication regimen includes:

- Escitalopram 20mg daily (for the last 2 years)
- Lorazepam 1mg as needed (which she takes approximately twice weekly)

During the interview today, Ms. D tells you that her family doctor has been managing her medications since her inpatient admission in 2015. At her last appointment, she told him about her pregnancy, and he referred her to a psychiatrist, Dr. T. When she met with Dr. T. he told her that she would likely not need medications during pregnancy as the “pregnancy hormones” would suffice, but that if she insisted that she needed medication, he could prescribe her only sertraline or bupropion. She was disappointed at this advice as neither of these medications have been helpful to her in the past. Additionally, she reports remission of her depression symptoms with escitalopram and is hesitant to change it and “start over.”

Through her own online research, she concluded the advice of Dr. T “just simply is not true” and decided to seek another opinion. She would like to discuss her medication options during pregnancy, but states that she also plans to discontinue all medications 1 month prior to birth in order to “not make my baby have to go through medication withdrawal.”

FACILITATOR PAUSES FOR DISCUSSION

1. How would you characterize the severity of Ms. D's illness? Why?

Elicit the following:

- Severe; symptoms that cause dysfunction: in bed 23.5 hours a day, hopelessness, anhedonia
- Onset in young adulthood, multiple episodes
- Genetic loading (revealed later in the history)
- History of suicidal thoughts
- History of multiple inpatient admission
- Multiple failed medication trials
- Comorbid anxiety symptoms



Psychiatric History, continued

Patient reports mild depressive symptoms currently, which she attributes to financial stress. Denies any current suicidal ideation.

No history of panic attacks, obsessions/compulsions, hallucinations, delusions or manic episodes.

Family Psychiatric History:

Mother: Depression

Father: Bipolar Disorder and Alcohol Use Disorder

Brother: Bipolar Disorder, anxiety, and substance abuse (specifics unknown)

Paternal Grandmother: history of completed suicide

Medical History:

Asthma, severe

Allergies: penicillin

No other pregnancies

Substance Use:

History of tobacco use; quit 2 years ago Occasional

alcohol use prior to pregnancy

No illicit drugs

Social History:

Patient lives with her mother and 2 siblings.

Patient was born and raised in a Cleveland suburb by both parents.

She was previously working in a “vape store” in New Mexico, “it was the first time I had a job that I loved,” but has been unemployed since moving back to Cleveland 3 months ago (when she learned of the pregnancy).

Boyfriend is the father of the baby, is still in New Mexico, but planning to move to Cleveland in the near future.

History of verbal and physical abuse by her father throughout her childhood; reports that her mother worked long hours while her father was disabled and was in the home “watching porn” and drinking most of the time.

MSE:

General: Patient appears well dressed and groomed, no abnormal movements

Speech: Normal rate and volume

Mood: Mildly anxious

Affect: Appropriate, bright, reactive Thought Process:

Linear, goal-directed

Thought Content: No delusions, no hallucinations, no suicidality, no homicidality, no ruminations or obsessions

Behavior: Friendly, polite, interactive

Cognitive: alert and oriented x 3, language fluent

Insight/Judgement: good/good



FACILITATOR PAUSES FOR DISCUSSION

1. What feedback would you give to Ms. D about the following?

- Her risk of recurrence during pregnancy

Elicit the following:

- Depression prevalence during the pregnancy/postpartum period is high in the general population (approximately 15%)
- Pregnancy is not protective (Studies show that hormonal changes do not decrease depression in pregnancy although individual women may find that a specific pregnancy may make their symptoms worse or better, with no guarantee that the next pregnancy will be the same)
- Ms. D's individual risk profile for recurrence is higher due to numerous previous depressive episodes

- Her risk of recurrence during the postpartum period

Elicit the following:

- Postpartum period is a time of highest vulnerability to relapse in psychiatric symptoms
- Women are 23x more likely to have a first psychiatric admission in the first month postpartum than at any other time in their lives
- Risk remains elevated for a year or more postpartum

- If she has a recurrence, the risks associated with acute depressive episodes during pregnancy and the postpartum period

Elicit the following:

- Untreated depression has risks in the pregnancy and postpartum periods
- Risk of suicide with untreated depression
- Ms. D's hypersomnia and risk of missing prenatal appointments
- Nutritional status
- Risk of relapse with cigarettes
- For an advanced audience: risks of preterm delivery, low birth weight

2. What would be your advice for Ms. D? What factors would you consider when selecting a medication for her to take during pregnancy?

Elicit the following:

- Untreated depression has risks in the pregnancy and postpartum periods
- Ms. D has had symptom stability with her current regimen of escitalopram and lorazepam
- Her baby has already been exposed to escitalopram, there are no contraindications to continuing it, and starting a new medication would be a new exposure to that medication and could include an exposure to untreated illness if it is ineffective
- Factors to consider with Ms. D: current symptom stability; previous treatment failures; regimen includes SSRI which is considered to be safe; destabilization has major implications/risks with her
- Factors to consider in general: previous treatment trials; previous pregnancies/postpartum periods; family history and treatment response in family
- Advice should be to continue current escitalopram but to explore whether lorazepam is conferring additional benefit and to see whether it can potentially be tapered to reduce the risk of respiratory depression in the baby



3. Suppose you kept her on escitalopram. What would you tell her about the risks associated with taking escitalopram in the 3rd trimester? What would you advise her about her plan to discontinue the medication in the last month of pregnancy?

Elicit the following:

- Not recommended to discontinue medications in the last month
- Postpartum depression risk is highest in the first month postpartum; discontinuation of medications prior to that leaves Ms. D untreated in the most vulnerable perinatal period
- Potential postpartum decreases in sleep and increases in family stress and conflict which are common with any new infant also increase risk
- Untreated depression in the postpartum period interferes with bonding and engagement with the newborn (which can have effects on attachment)

Teach the following (or elicit from a more advanced audience):

- Theoretical risk of persistent pulmonary hypertension of the newborn but highly unlikely and absolute risk, if it exists is very small
- Risk of poor neonatal adaptation syndrome: 25-30% of infants exposed to SSRIs may have symptoms of jitteriness, increased muscle tone, rapid breathing – but these are transient, self-limited, and not dangerous.
- One study of discontinuing SSRIs in the third trimester showed that this practice does not decrease the infant's risk of this syndrome

4. What non-medication recommendations would you have for Ms. D?

Elicit the following:

- Psychotherapy – Cognitive-Behavioral Therapy, Interpersonal Therapy
- Mindfulness for anxiety symptoms instead of lorazepam prn
- Enhance social supports – yoga, meditation
- Support groups for maintaining smoking cessation
- Trauma support groups

FACILITATOR SHOWS RISK-RISK DISCUSSION IN PREGNANCY VIDEO

FACILITATOR GIVES VERBAL INSTRUCTIONS FOR THE TABLE BELOW

1. Trainees divide into pairs
2. Based on Ms. D's case, fill in the middle column of the table
3. Once the tables have been completed, use them to practice how to talk to Ms. D about her individual risk profile
4. Open up for large group discussion.

Reproductive Domains	Risks Associated with Psychiatric Disorder	Risks Associated with SSRI Treatment
Congenital Malformations	Unlikely	Early studies: cardiac defects; PPHN (low absolute risk) More recent studies: no or very low association after corrections
Spontaneous Abortion	Unlikely	Equivocal studies; low odds ratios and same for women for stop SSRI prior to pregnancy
Length of Pregnancy	Preterm Delivery	Preterm delivery
Size Effects	Small for gestational age baby	Small for gestational age baby
Withdrawal (Short-Term Risks)	Impaired bonding with the baby in the postpartum period Increased risk of postpartum depression	Serotonergic withdrawal in newborn: - Gastrointestinal - Neuromuscular - Pulmonary - Psychiatric/behavioral Transient (24-48 hours); no treatment needed
Long-Term Risks (Development)	Long-term risks associated with poor bonding to baby/attachment to parent Maternal depression → increased risk of child developing depression	Developmental studies show promise: - Prospective trials show catching up of any initial delays - Behavioral problems also occur in children of mothers with depression Autism studies are poorly constructed; no associations when sibling analyses and paternal factors are included
Other (e.g., Obstetrical Risks)	For Ms. D: -Hypersomnia might lead her to miss prenatal appointments -Increased risk of suicide -Risk of resumption of smoking -Dietary changes?	None known



References

- Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, Polen KN, Reefhuis J. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. *JAMA Psychiatry*. 2020 Aug 5;77(12):1246–55. doi: 10.1001/jamapsychiatry.2020.2453. Epub ahead of print. PMID: 32777011; PMCID: PMC7407327.
- Andersen JT, Andersen NL, Horwitz H, Poulsen HE, Jimenez-Solem E. Exposure to Selective Serotonin Reuptake Inhibitors in Early Pregnancy and the Risk of Miscarriage. *Obstet Gynecol*. 2014 Sep 5.
- Bayrampour H, Kapoor A, Bunka M, Ryan D. The Risk of Relapse of Depression During Pregnancy After Discontinuation of Antidepressants: A Systematic Review and Meta-Analysis. *J Clin Psychiatry*. 2020 Jun 9;81(4):19r13134. doi: 10.4088/JCP.19r13134. PMID: 32558401.
- Byatt, Nancy, Kristina M. Deligiannidis, and Marlene P. Freeman. "Antidepressant use in pregnancy: a critical review focused on risks and controversies." *Acta Psychiatrica Scandinavica* 127.2 (2013): 94-114. Warburton, W., C. Hertzman, and T. F.
- Grote, Nancy K., et al. "A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction." *Archives of general psychiatry* 67.10 (2010): 1012-1024
- Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernández-Díaz, S. (2014). Antidepressant Use in Pregnancy and the Risk of Cardiac Defects. *New England Journal of Medicine*, 370(25), 2397–2407. <https://doi.org/10.1056/nejmoa1312828>
- Jarde A, Morais M, Kingston D, Giallo R, MacQueen GM, Giglia L, Beyene J, Wang Y, McDonald SD. Neonatal Outcomes in Women With Untreated Antenatal Depression Compared With Women Without Depression: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2016 Aug 1;73(8):826-37. doi: 10.1001/jamapsychiatry.2016.0934. PMID: 27276520.
- Mitchell J, Goodman J. Comparative effects of antidepressant medications and untreated major depression on pregnancy outcomes: a systematic review. *Arch Womens Ment Health*. 2018 Oct;21(5):505-516. doi: 10.1007/s00737-018-0844-z. Epub 2018 Apr 11. PMID: 29644439.
- Nonacs RM, Cohen LS. Challenges in Determining Outcomes of Prenatal Exposure to Antidepressants. *J Clin Psychiatry*. 2020 May 12;81(3):20com13269. doi: 10.4088/JCP.20com13269. PMID: 32412701.
- Nulman I, Koren G, Rovet J, et al. Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression. *Am J Psychiatry* 2012; 169: 1165–1174.
- Payne JL. Psychiatric Medication Use in Pregnancy and Breastfeeding. *Obstet Gynecol Clin North Am*. 2021 Mar;48(1):131-149. doi: 10.1016/j.ogc.2020.11.006. PMID: 33573783.
- Rommel AS, Bergink V, Liu X, Munk-Olsen T, Molenaar NM. Long-Term Effects of Intrauterine Exposure to Antidepressants on Physical, Neurodevelopmental, and Psychiatric Outcomes: A Systematic Review. *J Clin Psychiatry*. 2020 May 12;81(3):19r12965. doi: 10.4088/JCP.19r12965. PMID: 32412703.
- Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected Pregnancy and Delivery Outcomes After Exposure to Antidepressant Medication: A Systematic Review and Meta-analysis. *JAMA Psychiatry* 2013;70(4):436-443.
- Wisner KL, Oberlander TF, Huybrechts KF. The Association Between Antidepressant Exposure and Birth Defects-Are We There Yet? *JAMA Psychiatry*. 2020 Aug 5. doi: 10.1001/jamapsychiatry.2020.1512. Epub ahead of print. PMID: 32777006.



Yonkers, Kimberly A., et al. "The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists." *General hospital psychiatry* 31.5 (2009): 403-413.